View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 18, 2019

Pfizer to acquire US company Array BioPharma for $11.4bn

Pfizer has signed a definitive merger agreement to acquire US-based, commercial-stage biopharmaceutical company Array BioPharma.

Pfizer has signed a definitive merger agreement to acquire US-based, commercial-stage biopharmaceutical company Array BioPharma.

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

Valued at around $11.4bn, the deal is subject to customary closing conditions, including regulatory approvals and the tender of a majority of the outstanding shares of Array common stock.

Array BioPharma develops and commercialises targeted small molecule medicines for the treatment of cancer and other diseases. The company has a broad pipeline of targeted cancer medicines currently in development and a portfolio of out-licensed medicines.

Pfizer expects that the deal will help build its oncology drug pipeline.

Array BioPharma’s portfolio includes the approved combined use of Braftovi (encorafenib) and Mektovi (binimetinib) to treat BRAFV600E or BRAFV600K mutant unresectable and metastatic melanoma.

Pfizer CEO Albert Bourla said: “The proposed acquisition of Array strengthens our innovative biopharmaceutical business, is expected to enhance its long-term growth trajectory, and sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer’s existing expertise in breast and prostate cancers.”

Once the transaction closes, employees of Array BioPharma will join Pfizer at its Cambridge (Massachusetts) and Morrisville (North Carolina) offices, as well as its facility in Boulder, Colorado.

The majority of the transaction is expected to be financed by Pfizer, which expects to close the acquisition in the second half of this year.

Array BioPharma CEO Ron Squarer said: “Pfizer shares our commitment to patients and a passion for advancing science to develop even more options for individuals with unmet needs.”

Related Companies

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology